Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Trial Profile

Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2017

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Adrenocortical carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Apr 2017 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Feb 2017 New source identified and integrated (EudraCT2011-002873-47; European Clinical Trials Database).
    • 14 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top